OGEN - Oragenics shares results for COVID-19 vaccine candidate from second pre-clinical study

Oragenics (NYSE:OGEN) announced data from a hamster challenge study for the intranasal and intramuscular administration of its COVID-19 vaccine candidate. Five days after the viral challenge, both formulations of the vaccine led to “robust immune responses” and cut the COVID-19 viral loads to undetectable levels in nasal pathways and lungs, according to the company. Meanwhile, in the control group of animals, there was no detectable immune reaction and “substantial viral loads.” Despite the data supporting both routes of administration, the company intends to focus on the intranasal mode of delivery for the Terra CoV-2 vaccine due to multiple factors, including the lack of rivalry for the route and its potential advantages. Data from this second pre-clinical study for the vaccine will support the Oragenics’ (OGEN) Investigational New Drug filing to the FDA, expected in Q2 2022, Executive Chairman of the company Frederick W. Telling remarked. In August, Oragenics (OGEN) disclosed more

For further details see:

Oragenics shares results for COVID-19 vaccine candidate from second pre-clinical study